RT Journal Article
SR Electronic
T1 Discovering Subtypes with Imaging Signatures in the Motoric Cognitive Risk Syndrome Consortium using Weakly-Supervised Clustering
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.11.24315328
DO 10.1101/2024.10.11.24315328
A1 Nallapu, Bhargav Teja
A1 Ezzati, Ali
A1 Blumen, Helena M.
A1 Petersen, Kellen K.
A1 Lipton, Richard B.
A1 Ayers, Emmeline
A1 Kumar, V G Pradeep
A1 Velandai, Srikanth
A1 Beare, Richard
A1 Beauchet, Olivier
A1 Doi, Takehiko
A1 Shimada, Hiroyuki
A1 Milman, Sofiya
A1 Aleksic, Sandra
A1 Verghese, Joe
YR 2024
UL http://medrxiv.org/content/early/2024/10/13/2024.10.11.24315328.abstract
AB INTRODUCTION Understanding the heterogeneity of brain structure in individuals with the Motoric Cognitive Risk Syndrome (MCR) may improve the current risk assessments of dementia.METHODS We used data from 6 cohorts from the MCR consortium (N=1987). A weakly- supervised clustering algorithm called HYDRA was applied to volumetric MRI measures to identify distinct subgroups in the population with gait speeds lower than one standard deviation (1SD) above mean.RESULTS Three subgroups (Groups A, B & C) were identified through MRI-based clustering with significant differences in regional brain volumes, gait speeds, and performance on Trail Making (Part-B) and Free and Cued Selective Reminding Tests.DISCUSSION Based on structural MRI, our results reflect heterogeneity in the population with moderate and slow gait, including those with MCR. Such a data-driven approach could help pave new pathways toward dementia at-risk stratification and have implications for precision health for patients.Competing Interest StatementHMB serves as a consultant for Neural+. RBL is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He also receives support from the Migraine Research Foundation and the National Headache Foundation and research grants from TEVA, Satsuma and Amgen. He serves on the editorial board of Neurology, senior advisor to Headache, and associate editor to Cephalalgia. He has reviewed for the NIA and NINDS, holds stock and stock options in Axon, Biohaven Holdings, CoolTech and Manistee; serves as consultant, advisory board member, or has received honoraria from: Abbvie (Allergan), American Academy of Neurology, American Headache Society, Amgen, Avanir, Axon, Axsome, Biohaven, Biovision, Boston Scientific, Dr. Reddys (Promius), Electrocore, Eli Lilly, eNeura Therapeutics, Equinox, GlaxoSmithKline, Grifols, Lundbeck (Alder), Manistee, Merck, Pernix, Pfizer, Satsuma, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolffs Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa. JV serves as an Advisory Committee Member for MedRhythms, and a holds a uncompensated voluntary position at CatchU. Authors BTN, AE, KKP, EA, VGPK, SV, RB, OB, TD, HS, SM, and SA do not have any conflicts of interest to disclose.Funding StatementThis study was supported by NIH/NIA grants: 1R56AG057548-01, R01AG057548-01A1 and 2R01AG039330 (JV), NIH RO1 DK129320-01 2021-2026 (RB), NIA R01AG062659-01A1 (HB), NIA K23 AG063993, AG080635, AG003949, the Alzheimers Association (SG-24-988292 ISAVRAD); Cure Alzheimers Fund, the Leonard and Sylvia Marx Foundation (AE, RL), NIH/NIA 1K76AG083274 (SA). None of the funding sources had any role in the conduct of the analysis, interpretation of data and preparation of the article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Albert Einstein College of Medicine, bronx, NY, USA gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors